FUDANZHANGJIANG (01349.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec25

Fudan Zhangjiang Receives Acceptance for Clinical Trial Application of FZ-P001 Sodium

10:32

Oct31

Fudan Zhangjiang Changes A-Share Raised Funds Purpose to Support Photodynamic Drug R&D

15:31

Oct30

FUDANZHANGJIANG released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue HKD 598.71 M, actual EPS HKD -0.0846

11:00

FUDANZHANGJIANG released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue HKD 175.99 M, actual EPS HKD -0.0906

11:00

Oct22

FUDANZHANGJIANG to Release FY2025 Q3 Earnings on October 30 After-Market BJT

02:33

Oct13

Affiliate of Fudan Zijang's Obeticholic Acid Tablets Application for Market Approval Rejected

10:04

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 175.99 M, Net Income -23.67 M, EPS -0.0906

Aug25

Distribution Plan(CST)

Cash dividend 0.0321 HKD

Aug12

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 230.04 M, Net Income 3.338 M, EPS 0.0032

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change